

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> A61K 31/415, 31/365, 31/665, 31/615, 31/425, 31/505, 9/14, 9/52		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/27598</b>
			<b>(43) International Publication Date:</b> 8 December 1994 (08.12.94)
<b>(21) International Application Number:</b> PCT/AU94/00272		<b>(74) Agent:</b> SPRUSON & FERGUSON; G.P.O. Box 3898, Sydney, NSW 2001 (AU).	
<b>(22) International Filing Date:</b> 24 May 1994 (24.05.94)			
<b>(30) Priority Data:</b> PL 9030 26 May 1993 (26.05.93) AU		<b>(81) Designated States:</b> AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
<b>(71) Applicants (for all designated States except US):</b> COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION [AU/AU]; Limestone Avenue, Campbell, ACT 2601 (AU). MEAT RESEARCH CORPORATION [AU/AU]; Level 6, 26 College Street, Sydney, NSW 2000 (AU).		<b>Published</b> With international search report.	
<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HENNESSY, Desmond, Ronald [AU/AU]; 12 Harper Street, North Epping, NSW 2121 (AU). ASHES, John, Richard [AU/AU]; 19 Lisa Valley Close, Wahroonga, NSW 2076 (AU). SCOTT, Trevor, William [AU/AU]; 41 Arnold Avenue, Kellyville, NSW 2155 (AU). GULATI, Suresh, Kumar [AU/AU]; 20 Daffodil Street, Eastwood, NSW 2122 (AU). STEEL, John, Winston [AU/AU]; 4 The Bartizan, Castlecrag, NSW 2068 (AU).			
<b>(54) Title:</b> ANTIPARASITIC COMPOSITIONS			
<b>(57) Abstract</b> <p>This invention concerns the delivery of anti-parasitic agents to ruminant animals. More particularly, the invention concerns delivery of such agents in a controlled manner to enable the agent to have maximum effect on the parasite for longer times than is possible with conventional formulations. The composition of the invention comprises a benzimidazole, macrocyclic lactone, organophosphate, salicylanilide/substituted phenol, tetramisole or pyrimidine anti-parasitic agent dispersed in a medium the solubility characteristics of which are such as to ensure that, following oral administration, controlled amounts of the anti-parasitic agent become available to the parasite, either directly or by absorption into the ruminant blood plasma, during passage of the composition through the rumen, the abomasum and the intestine.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## Antiparasitic Compositions

### Technical Field

This invention concerns the delivery of anti-parasitic agents to ruminant animals. More particularly, the invention concerns delivery of such agents in a controlled manner to enable the agent to have maximum effect on the parasite for longer times than is possible with conventional formulations.

### Background Art

Anti-parasitic agents are frequently delivered to ruminants in the form of oral drenches directly into the rumen. Because of chemical and bacterial degradation, association with digesta, uncontrolled absorption and excretion, the dosages required for useful effect will generally need to be considerably in excess of what might be anticipated from observation of *in vitro* exposure of a parasite to a given anti-parasitic agent. The elevated dosages are undesirable not only from the direct cost point of view, but also because of the contribution to the accumulation of chemical residues (i) in edible tissues and, (ii) in the environment as they are excreted from the animal.

The present invention avoids the aforementioned disadvantages associated with prior art anti-parasitic agent administration, in that it permits greater anti-parasitic action to be achieved with existing dosages, or allows existing rates of parasite control to be maintained with lower dosage rates. The invention is based on the discovery of a novel concept of staged delivery of anti-parasitic agent to three sites, the rumen, the abomasum and the small intestine.

An important function of the rumen is to break down materials ingested by the animal in order to facilitate their absorption and utilisation. There are some nutrients from which better economic benefits would be derived if they were to pass unchanged through the rumen to become available for absorption from the abomasum or the small intestine. For example, it has been known for many years that the amino acid methionine is substantially degraded in the rumen, and that the introduction of methionine directly into the abomasum can lead to enhanced wool growth.

Ferguson *et al.* (1969)<sup>1</sup> and Scott *et al* (1972)<sup>2</sup> describe chemical carriers or coatings designed to provide feedstuffs, including amino acids, with substantially 100% protection from rumen degradation so as to enhance ruminant productive capacity. Those disclosures were specifically directed to nutritional improvement. They did, however, allude to the possibility of the various protectants having value for transporting therapeutic and prophylactic agents. Evidence that this might be so was provided by work reported by Hennessy *et al*<sup>3</sup>, which indicated that oral administration of albendazole (ABZ) protected from rumen degradation by

encapsulation in a simple formaldehyde-treated lipid/protein matrix resulted in an increased concentration of ABZ in abomasal fluid compared with that following oral dosage with a conventional formulation from which the ABZ was freely presented to the rumen. While such prior art is acknowledged as a precursor of the present invention, the present invention is distinguished by its use of the surprising finding that the efficacy of anti-parasitic agents can be dramatically improved by administering them in a form which specifically and proportionally divides the dose and ensures a *controlled* degree of availability at various sites in the gastrointestinal tract, *including the rumen, abomasum and small intestine*.

Conventionally (oral) administered benzimidazole anthelmintic compounds are rapidly absorbed, predominantly from the rumen, and are extensively metabolised (with concomitant reduction in metabolite potency) before excretion in urine and bile. This behaviour significantly limits the availability of active metabolites at the sites of parasite infection - namely the lumen of the abomasum and small intestine.

Absorption of macrocyclic lactones from the rumen initiates similar metabolism. In addition, some chemical degradation of the active occurs within the rumen as well as extensive (and strong) association of active with rumen digesta material. This association also significantly limits availability and it is suggested that it contributes to the large portion of the dose which is transported through the gastrointestinal tract, potentially unavailable for contact with the parasite. Large quantities of active parent drug are then excreted in faeces and it is these contaminants in faeces that are considered to deleteriously impact on fauna beneficial in pasture degradation of the faecal material. Organophosphates function by inhibiting enzymes, particularly acetyl choline esterase in the parasite and host. The compounds are rapidly absorbed from the rumen which causes a corresponding rapid depression of enzyme activity in the host, in many cases this is lethal. Organophosphates therefore have a very low safety index. Reducing the rapid absorption of organophosphates from the rumen and extending or directing their availability to parasites in the abomasum and intestine is advantageous in that toxicity to the host would be reduced while maintaining antiparasitic activity.

Salicylanilides such as closantel very strongly associate with plasma albumin. This action retains the drug in the bloodstream at levels that are efficacious against blood-consuming parasites for prolonged periods (about 3-4 weeks), providing an obvious prophylactic effect. Closantel is, however, slowly absorbed and about 50% of the dose is lost in faeces as the dose bolus is naturally transported in digesta past the site(s) of absorption in the gastrointestinal tract. Controlling the dose by broader presentation at the rumen, abomasum and intestine can increase quantitative absorption and by definition of the pharmacokinetic behaviour of closantel, the residence time and therefore protective period can be extended.

Levamisole and the morantel/pyrantel chemical class of antiparasitic agents are rapidly absorbed from the rumen, the maximum concentrations in the bloodstream occurring within 2-4 hours of oral administration. They are rapidly metabolised, in the case of morantel/pyrantel the absorbed compound is degraded  
5 at a rate consistent with first-pass metabolism; the products then being completely inactive. Absorption and metabolism can be so extensive that insufficient dose is even available to affect parasites at distal sites of the intestine, this being of significant importance since only drug which is retained in the gut is active. Absorbed drug is rapidly excreted, predominantly in urine. By reducing absorption  
10 from the rumen and directing large portions of the dose to the abomasum and intestine a greater availability of active drug to the parasite in the gut lumen is obtained.

While some absorption of drug from the rumen can define the initial availability of drug as this portion recycles between the bloodstream and  
15 gastrointestinal tract before clearance, it is crucial that absorption from the rumen be controlled and restricted to minimise loss of active from the gut environment. The absorption from the rumen, or degradation/association with rumen digesta severely limits the availability of a highly active parent compound at the site of parasite habitation, in the lumen of the abomasum and small intestine.

20 Traditionally, increased anthelmintic action (particularly against drench resistant parasites) necessitated the administration of multiple dose rates. This is costly and in some cases lethal to the host animal. Furthermore, the value of increased dose is limited since the dose is cleared following first-order kinetics, that is, the clearance is directly related to the quantity of drug present. The high  
25 concentrations that appear in the bloodstream after rapid and extensive absorption from the rumen are not available to the parasite for significantly longer duration than that achieved following a single dose. Because it is the duration of availability of an antiparasitic agent at the site of infection that is critical for activity the rapidly cleared, albeit initially high, concentrations are of little additional value.

30 By restricting absorption from the rumen and controlling the quantity of a single dose which is presented to the lumen of the abomasum and small intestine, similar increased activity against resistant parasites is achieved with the staged delivery of a single dose compared with the more expensive administration of multiple dose rates.

35

### Disclosure of the Invention

In its broadest aspect this invention provides a particulate composition for combating and preventing parasite infestation of ruminants, which composition comprises a benzimidazole, macrocyclic lactone, organophosphate, salicylanilide/substituted phenol, tetramisole or pyrimidine anti-parasitic agent

dispersed in a medium the solubility characteristics of which are such as to ensure that, following oral administration, controlled amounts of the anti-parasitic agent become available to the parasite, either directly or by absorption into the ruminant blood plasma, during passage of the composition through the rumen. the abomasum  
5 and the intestine.

The benzimidazole antiparasitic agents include 2-(4-thiazolyl)-1H-benzimidazole, known as thiabendazole; [5-(propylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester, known as albendazole, [5-(propylsulfinyl)-1H-benzimidazol-2-yl]carbamic acid methyl ester known as albendazole sulfoxide or  
10 albendazole oxide; [2-(4-thiazolyl)-1H-benzimidazol-5-yl]carbamic acid 1-methylethyl ester, known as cambendazole; [5-(phenylthio)-1H-benzimidazol-2-yl]carbamic acid methyl ester, known as fenbendazole; (5-benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester, known as mebendazole; [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamic acid methyl ester, known as  
15 oxfendazole. (5-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester, known as oxibendazole. [5-(n-butyl)-1H-benzimidazol-2-yl]carbamic acid methyl ester known as parbendazole. methyl 5-cyclopropylcarbonyl-1H-benzimidazol-2-ylcarbamate known as ciclo bendazole. methyl 5-(4-fluorobenzoyl)-1H-benzimidazol-2-ylcarbamate known as flubendazole. 5-chloro-6-(2,3-  
20 dichlorophenoxy)-2-(methylthio)-benzimidazole known as triclabendazole and [5-(4-fluoro-phenylsulfonyloxy)-1H-benzimidazol-2-yl]carbamic acid methyl ester known as luxabendazole.

The benzimidazole antiparasitic agents are active against *Haemonchus*, *Ostertagia*, *Trichostrongylus*, *Nematodirus*, *Cooperia*, *Bunostomum*,  
25 *Strongyloides*, *Trichuris*, *Oesophagostomum*, *Chabertia*, *Dictyocaulus*, *Moniezia* and *Fasciola* in sheep. They are active against *Haemonchus*, *Ostertagia*, *Trichostrongylus*, *Nematodirus*, *Cooperia*, *Bunostomum*, *Capillaria*, *Strongyloides*, *Trichuris*, *Oesophagostomum*, *Chabertia*, *Dictyocaulus*, *Moniezia* and *Fasciola* in cattle.

30 The macrocyclic lactone antiparasitic agent may be an avermectin or milbemycin, such as abamectin, ivermectin, doramectin or moxidectin.

The macrocyclic lactone antiparasitic agents are active against *Haemonchus*, *Ostertagia*, *Trichostrongylus*, *Nematodirus*, *Cooperia*, *Strongyloides*, *Trichuris*, *Oesophagostomum*, *Chabertia* and *Dictyocaulus* in sheep. They are active against  
35 *Haemonchus*, *Ostertagia*, *Trichostrongylus*, *Nematodirus*, *Cooperia*, *Oesophagostomum* and *Dictyocaulus* in cattle.

Organophosphate antiparasitic agents include bis(2-chloroethyl)-3-chloro-4-methylcoumarin-7-yl phosphate known as haloxon, tetraethyl-[(2-methoxy-p-phenylene)-bis-[imino(thiocarbonyl)]]diphosphoramidate known as imcarbophos,  
40 diethyl naphthylimido-oxyphosphonate known as naphthalophos.

The organophosphate antiparasitic agents are active against *Haemonchus*, *Trichostrongylus*, *Cooperia*, *Oesophagostomum* and *Dictyocaulus* in sheep. They are active against *Haemonchus*, *Ostertagia*, *Trichostrongylus*, *Cooperia*, *Bunostomum* and *Oesophagostomum* in cattle.

5 Salicylanilide/substituted phenol antiparasitic agents include 5'-chloro-4'-(4-chloro- $\alpha$ -cyanobenzyl)-3,5-diiodosalicyl-o-toluidide known as closantel, 2'-[2,3-bis-(methoxycarbonyl)guanidino]-5'-phenylthio-2-methoxyacetanilide known as febantel, 3,3',5,5',6-pentachloro-2'-hydroxysalicylanilide known as oxyclozanide, 3'-chloro-4'-(4-chlorophenoxy)-3,5-diiodosalicylanilide known as rafoxanide, 2'.5-10 dichloro-4'-nitrosalicylanilide known as niclosamide, 4-cyano-2-iodo-6-nitrophenol known as nitroxylin. *In vivo*, febantel is metabolised to fenbendazole.

The salicylanilide/substituted phenol antiparasitic agents are active against *Haemonchus* and *Fasciola* in sheep. They are active against *Haemonchus*, *Bunostomum*, *Oesophagostomum*, *Moniezia*, *Fasciola* and *Paramphistomum* in 15 cattle.

Tetramisole antiparasitic agents include (-)-(S)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride known as levamisole.

The tetramisole antiparasitic agents are active against *Haemonchus*, *Ostertagia*, *Trichostrongylus*, *Nematodirus*, *Cooperia*, *Bunostomum*, *Strongyloides*, 20 *Trichuris*, *Oesophagostomum*, *Chabertia* and *Dictyocaulus* in sheep. They are active against *Haemonchus*, *Ostertagia*, *Trichostrongylus*, *Nematodirus*, *Cooperia*, *Bunostomum*, *Oesophagostomum*, *Chabertia*, *Dictyocaulus* and *Thelazia* in cattle.

Pyrimidine antiparasitic agents include 1,4,5,6-tetrahydro-1-methyl-2-[(E)-2-(2-thienyl)-vinyl]-pyrimidine-4,4'-methylenebis-(3-hydroxy-2-naphthoate) known as 25 pyrantel, (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(3-methyl-2-thienyl)vinyl]-pyrimidine known as morantel, (E)-3-[2-(1,4,5,6-tetrahydro-1-methylpyrimidin-2-yl)vinyl]phenol-4,4-methylenebis-(3-hydroxy-2-naphthoate) known as oxantel, and salts of any, including citrate, tartrate and pamoate(embonate).

The pyrimidine antiparasitic agents are active against *Haemonchus*, 30 *Ostertagia*, *Trichostrongylus*, *Nematodirus*, *Cooperia*, *Trichuris*, *Oesophagostomum* and *Chabertia* in sheep. They are active against *Haemonchus*, *Ostertagia*, *Trichostrongylus*, *Nematodirus*, *Cooperia*, *Oesophagostomum* and *Chabertia* in cattle.

In a preferred embodiment of this invention the anti-parasitic agent is 35 dispersed in a protein/lipid medium possessing solubility characteristics selected to ensure the release of amounts of the active agent at sites in the intestinal tract. Preferred media are based on modified proteins, for example, proteinaceous substances such as plant or animal meals, casein and gelatin, which have been treated with cross-linking agents, eg. aldehydes, tannins, polyvalent cations and the 40 like, or otherwise modified (eg. by heating) to acquire solubility characteristics



offering preselected degrees of resistance to the various environments encountered in the ruminant gastrointestinal tract.

Accordingly, another aspect of this invention is a composition for combating and preventing parasite infestation of ruminants which comprises a benzimidazole, 5 macrocyclic lactone, organophosphate, salicylanilide/substituted phenol, tetramisole or pyrimidine anti-parasitic agent dispersed in a proteinaceous matrix which undergoes staged degradation allowing controlled release of the anti-parasitic agent in each of the rumen, abomasum and intestine.

The degradation of proteinaceous media such as referred to above will occur 10 firstly in the rumen through the activity of the microbial population, next in the abomasum where the more acidic conditions further solubilise the matrix, and finally in the small intestine due to enzymatic breakdown of proteins and fats.

In the case of lipid/protein matrices wherein the protein has been cross-linked by treatment with an aldehyde, we have found it possible, by varying the 15 proportions of ingredients and the degree of cross-linking, to provide formulations which will degrade at selected gastrointestinal sites in a predetermined way. This means that formulations can be tailored so that the active ingredient is released according to the pattern felt to be most conducive to its efficacy.

When the anti-parasitic agent is a benzimidazole, compositions according to 20 this invention should ensure that the relative proportions of anti-parasitic agent which become available in the rumen, the abomasum and the small intestine are of the order of 1:4:5 respectively. For macrocyclic lactones the conventional availability is about 1:0.1:20 respectively, whereas rumen, abomasum and small intestine availabilities of 1:2:30 are likely to be more suitable. Appropriate 25 availabilities for other classes of agents may be determined by routine experimentation.

### Brief Description of the Drawings

Figure 1 illustrates the levels of formaldehyde treatment to achieve various degrees of protection.

30 Figures 2 and 3 illustrate the release of benzimidazoles and macrocyclic lactones from variously protected protein matrices when incubated in fluid from the rumen, abomasum and small intestine under simulated *in vivo* conditions.

Figure 4 shows the albendazole sulfoxide (ABZ.SO) plasma profiles of sheep into which ABZ had been intra-uminally (IR) injected at a common dose rate of 35 3.9mg ABZ/kg bodyweight.

Figure 5 shows the abomasal fluid profiles for ABZ which were determined during the trial described in Example 5.

Figure 6 shows the ABZ.SO plasma profiles after intra abomasal administration. Figure 7 shows the concentration of ivermectin in plasma after IR administration at a common dose of 200µg/kg.

Figure 8 shows the concentration of ivermectin in abomasal fluid after IR administration at a common dose of 200µg/kg.

Figure 9 shows the concentration-with-time profiles of ABZ.SO in plasma of cattle after IR administration of ABZ at a common dose rate of 7.5mg/kg.

Figure 10 shows the concentration-with-time profiles of ABZ in abomasal fluid of cattle after IR administration of ABZ at a common dose rate of 7.5mg/kg.

Figure 11 shows the concentration-with-time profiles of ABZ.SO in abomasal fluid of cattle after IR administration of ABZ at a common dose rate of 7.5mg/kg.

### Best Mode or Modes of Carrying Out the Invention

Figure 1 illustrates the levels of formaldehyde treatment required to achieve various degrees of protection. Figures 2 and 3 illustrate the release of benzimidazoles and macrocyclic lactones from variously protected protein/lipid matrices when incubated in fluid from the rumen, abomasum and small intestine under simulated *in vivo* conditions. By reference to these figures the man skilled in the art should have no difficulty in designing formulations which will significantly enhance the efficacy of such agents. By routine experimentation it should be possible to design formulations for the delivery of other classes of anti-parasitic agents. Trials undertaken with sheep and cattle indicate that benzimidazole anthelmintic preparations according to this invention will increase the availability of the agent to a degree which leads to the elimination of up to 30% more benzimidazole-resistant worms than is achieved by the same dosage of a conventional benzimidazole preparation.

The invention will now be described in greater detail with reference to the following examples:

### Example 1

#### Preparation of 3-stage release anti-parasitic formulation

(a) Benzimidazole.

40g ABZ were evenly dispersed in 20mL vegetable oil, and the mixture was emulsified with 14% casein solution at pH 9. The emulsion was then freeze-dried and comminuted to form finely dispersed particles containing ABZ, oil and protein in ratios of about 4:2:4 by weight. These particles were treated with formalin (37% formaldehyde), the desired rate being between 0.5 and 0.85% HCHO to protein in a sealed mixer and stored in a closed container for 8 days.

**(B) Macrocyclic lactone**

100mg ivermectin (IVM) dissolved in 1mL methylethyl ketone was mixed with 2mL vegetable oil and then emulsified with 14% casein solution at pH 9. The emulsion was then freeze dried and comminuted to form finely dispersed particles containing IVM, oil and protein in ratios of about 1:20:20 by weight. These particles were treated with formaldehyde as described above in example 1(a).

**Example 2****Release of ABZ or IVM from a staged-release preparation**

Samples each containing approximately 5mg of ABZ or 0.15mg IVM were incubated *in vitro* in rumen fluid at 39°C, and the ABZ or IVM content of the fluid was determined at fixed intervals thereafter. Figures 2 and 3 show that within 8 hours less than 10% of the staged-release ABZ or IVM preparation had become available. (The mean residence time of materials in the rumen is about 10 hours).

**Example 3****15 Availability in the abomasum of ABZ from a staged-release preparation**

Samples similar to those described in Example 1(a) and (b) were incubated *in vitro* at 39°C in freshly collected sheep abomasal fluid. Analyses of fluid samples are presented in Figures 2 and 3 and show that approximately 40% of ABZ and 15% of IVM is released from the respective staged release preparation within 2 hours (the normal residence time of materials in the abomasum is between 1 and 3 hours).

**Example 4****Relative availabilities of ABZ and IVM in the intestine**

Sample ABZ and IVM preparations similar to those described in Example 1(a) and (b) were incubated *in vitro* at 39°C in fresh fluid collected from the upper 3m of the small intestine of sheep. From Figures 2 and 3 it will be seen that there is rapid release of solubilised ABZ and IVM from the staged-release form. The higher concentration of solubilised ABZ and IVM is probably due to the oil component of the particles increasing the partitioning of the ABZ and IVM into digesta fluid.

**Example 5****Comparison of rumen absorption *in vivo***

Figure 4 shows the ABZ.SO plasma profiles of sheep into which ABZ had been intra-uminally (IR) injected at a common dose rate of 3.9mg ABZ/kg

bodyweight in preparations similar to those described in Example 1(a). For comparison, ABZ was also administered at 3.9mg/kg as the commercial preparation "Valbazen".

The potential benefits of the rapid absorption of ABZ from the conventional preparation are not fully realised because much of the drug is excreted in the urine, whereas the slower uptake of ABZ from the staged-release preparation is more than compensated for by its release and higher availability in the abomasum and small intestine. Once the staged-release preparation has passed from the rumen and begins to degrade in the abomasum and small intestine, the dispersal of its ABZ component into the plasma, body tissues and the like then follows a similar time profile as that for ABZ administered in the conventional form. The abomasal fluid profiles for ABZ which were determined during the trial described in Example 5 are shown in Figure 5. These clearly show the greater availability of ABZ from the staged-release preparation. Again, once degradation of the particles is complete (after 24-30h), the elimination of ABZ from staged-release and conventional preparations occurs at a similar rate.

#### Example 6

##### Absorption of staged-release ABZ after entry into the small intestine

Samples similar to those described in Example 5 were administered by cannula directly into the abomasum (where virtually no absorption of ABZ takes place, but where the acidity of the environment brings about further degradation of the protective medium before it passes to the small intestine). Plasma samples were taken regularly thereafter and analysed for ABZ and its metabolites. The results are depicted in Figure 6, and show that there is a greater absorption of ABZ from the staged-release preparation; this is believed to be due to the solubilising affect of the lipid component of the protective medium.

#### Example 7

##### Anti-parasitic agent efficacies of the staged-release preparation and a conventional oral preparation

Sheep were dosed intra-uminally (at the rate of 3.9mg/kg bodyweight) with "Valbazen" or with a preparation as described in Example 1. Total worm counts were carried out on test animals slaughtered after 10 days. The results are shown in the following table:

10

Treatment	<i>H. contortus</i>		<i>T. colubriformis</i>	
	Count	Efficacy (%)	Count	Efficacy (%)
Control	3088	0	5699	0
Valbazen	667	78	2122	62
S/R	358	88	633	89

S/R = Staged-release preparation of ABZ

"Valbazen" (a registered trade mark) is an ABZ containing drench formulated by SmithKline Beecham Animal Health.

### Example 8

#### 5 Comparison of absorption of IVM from the rumen

Figure 7 shows the IVM profile of sheep which had been intra-ruminally injected with IVM at the rate of 0.2mg/kg either as the commercial product "Ivomec" or as a protected IVM formulation similar to that described in Example 1(b).

10 The absorption of commercial IVM is limited since much of the dose strongly associates with digesta material or is degraded in the rumen, thus limiting availability for absorption from the abomasum and intestine. The benefit of protected IVM is that a greater proportion of the dose is presented to the abomasum and intestine in the form which is available for absorption. This  
15 absorption produces a protracted profile of higher concentrations.

Initial appearance of IVM in the abomasal fluid did not differ between the two formulations since much of the drug which enters the abomasum quickly associates with digesta material. That is not to say that a greater quantity of IVM, following administration of the protected formulation, would not be released in the abomasum  
20 as described in relation to *in vitro* investigations (Figure 3). Although IVM released *in vivo* would quickly pass from the fluid to particulate digesta its increased presence is not readily determined due to the difficulty of separating the IVM released from formulation particles, but associated with fine digesta material, from IVM remaining in the formulated particles. Accordingly, the HPLC assay  
25 for IVM in the abomasum was restricted to fluid only, but it is reasonable to expect that the behavior of the IVM in fluid would reflect overall availability in abomasal digesta.

The greatly prolonged availability of IVM, as shown in plasma (Figure 7) reflected an increased presence of IVM in abomasal fluid at concentrations greater  
30 than those following administration of the commercial preparation (Figure 8).

**Example 9****Comparison of the availability of ABZ after administration to cattle**

Figure 9 shows the ABZ.SO plasma profiles of cattle into which ABZ had been intra-uminally injected as the commercial preparation "Valbazen", or as  
5 protected formulations as described in Example 1(a), at a common dose rate of 7.5mg ABZ/kg bodyweight. The concentrations of ABZ.SO increased similarly following administration of each formulation to 13 hours, but unlike the commercial product, ABZ.SO deriving from degradation of the protected formulations continued to rise to a maximum about 24 hours after administration,  
10 resulting in a much broader concentration-time profile.

In the abomasum, the quantity of ABZ and ABZ.SO in digesta fluid was greatly enhanced with the protected formulation increasing the concentration and duration of drug availability (Figures 10 and 11).

In the foregoing examples the references to the ABZ content of rumen and  
15 other intestinal fluids are references to the solubilised ABZ content of fluids from which solids had been spun out, and which were determined using the high performance liquid chromatography procedures described by Hennessy *et al* 1989<sup>4</sup>.

**Industrial Applicability**

The compositions and methods of the invention find use in animal health  
20 applications and simplify the administration of anti-parasitic agents to ruminants.

**References**

- 1 Australian Patent 402712
- 2 Australian Patent 450530
- 3 Hennessy *et al* at the Joint Conference of the New Zealand and Australian  
25 Societies for Parasitology, Auckland 1992
- 4 Hennessy *et al* 1989, (*Journal of Veterinary Pharmacology and Therapeutics*, 12, 421-429).

## Claims

1. A particulate composition for combating and preventing parasite infestation of ruminants, which composition comprises a benzimidazole, macrocyclic lactone, organophosphate, salicylanilide/substituted phenol, tetramisole or pyrimidine anti-parasitic agent dispersed in a medium the solubility characteristics of which are such as to ensure that, following oral administration, controlled amounts of the anti-parasitic agent become available to the parasite, either directly or by absorption into the ruminant blood plasma, during passage of the composition through the rumen, the abomasum and the intestine.
2. The composition of claim 1 wherein the antiparasitic agent is a benzimidazole or macrocyclic lactone.
3. The composition of claim 1 or claim 2, wherein the benzimidazole antiparasitic agent is thiabendazole, albendazole, albendazole sulfoxide or albendazole oxide, cambendazole, fenbendazole, mebendazole, oxfendazole, oxibendazole, parbendazole, ciclo bendazole, flubendazole, triclabendazole or luxabendazole.
4. The composition of claim 1 or claim 2, wherein the macrocyclic lactone antiparasitic agent is an avermectin or milbemycin.
5. The composition of claim 4, wherein the avermectin or milbemycin is abamectin, ivermectin, doramectin or moxidectin.
6. The composition of claim 1, wherein the medium possesses solubility characteristics selected to ensure the release of amounts of the active agent at sites in the intestinal tract.
7. The composition of claim 6, wherein the medium is based on a modified protein, which has been treated with cross-linking agents, or otherwise modified to acquire solubility characteristics offering preselected degrees of resistance to the various environments encountered in the ruminant gastrointestinal tract.
8. The composition of claim 7, wherein the medium is based on plant or animal meals, casein or gelatin.
9. The composition of claim 7 wherein the cross-linking agent is an aldehyde, tannin or polyvalent cation.
10. The composition of claim 7, wherein cross-linking is effected by heating.
11. The composition of claim 7 wherein the degree of cross-linking has been selected by reference to Figures 1 and 2 or 3.
12. The composition of claim 1, wherein the antiparasitic agent is dispersed in a lipid/protein matrix which has been cross-linked by treatment with an aldehyde.
13. A composition for combating and preventing parasite infestation of ruminants which comprises a benzimidazole, macrocyclic lactone,

organophosphate, salicylanilide/substituted phenol, tetramisole or pyrimidine anti-parasitic agent dispersed in a proteinaceous matrix which undergoes staged degradation allowing controlled release of the anti-parasitic agent in each of the rumen, abomasum and intestine.

5 14. A method for combating and preventing parasite infestation of a ruminant, which method comprises the oral administration to the ruminant of a benzimidazole, macrocyclic lactone, organophosphate, salicylanilide/substituted phenol, tetramisole or pyrimidine anti-parasitic agent dispersed in a medium the solubility characteristics of which are such as to ensure that, following  
10 administration, controlled amounts of the agent become available to the parasite, either directly or by absorption into the ruminant's blood plasma, during passage of the agent dispersed in the medium through the rumen, the abomasum and the intestine of the ruminant.

15 15. The method of claim 14 wherein the antiparasitic agent is a benzimidazole or macrocyclic lactone.

16. The method of claim 14 or claim 15, wherein the benzimidazole antiparasitic agent is thiabendazole, albendazole, albendazole sulfoxide or albendazole oxide, cambendazole, fenbendazole, mebendazole, oxfendazole, oxibendazole, parbendazole, ciclo bendazole, flubendazole, triclabendazole or  
20 luxabendazole.

17. The method of claim 14 or claim 15, wherein the macrocyclic lactone antiparasitic agent is an avermectin or milbemycin.

18. The method of claim 17, wherein the avermectin or milbemycin is abamectin, ivermectin, doramectin or moxidectin.

25 19. The method of claim 14, wherein the medium possesses solubility characteristics selected to ensure the release of amounts of the active agent at sites in the intestinal tract.

20. The method of claim 19, wherein the medium is based on a modified protein, which has been treated with cross-linking agents, or otherwise modified to  
30 acquire solubility characteristics offering preselected degrees of resistance to the various environments encountered in the ruminant gastrointestinal tract.

21. The method of claim 19, wherein the medium is based on plant or animal meals, casein or gelatin.

22. The method of claim 19, wherein the cross-linking agent is an aldehyde,  
35 tannin or polyvalent cation.

23. The method of claim 19, wherein cross-linking is effected by heating.

24. The method of claim 20 wherein the degree of cross-linking has been selected by reference to Figures 1 and 2 or 3.

25. The method of claim 14, wherein the antiparasitic agent is dispersed in a  
40 lipid/protein matrix which has been cross-linked by treatment with an aldehyde.



26. A method for combating and preventing parasite infestation of a ruminant, which method comprises oral administration to the ruminant of a benzimidazole, macrocyclic lactone, organophosphate, salicylanilide/substituted phenol, tetramisole or pyrimidine anti-parasitic agent dispersed in a proteinaceous  
s matrix which undergoes staged degradation allowing controlled release of the agent in each of the rumen, abomasum and intestine of the ruminant.

1/11





FIGURE 1:


2/11

FIGURE 2



3/11

FIGURE 3.



4/11




Figure 4:




Figure 5:




Figure 6:




FIGURE 7:






FIGURE 8:




FIGURE 9:




FIGURE 10:

11/11





FIGURE 11:

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int. Cl. <sup>5</sup> A61K 31/415, 31/365, 31/665, 31/615, 31/425, 31/505, 9/14, 9/52  According to International Patent Classification (IPC) or to both national classification and IPC					
<b>B. FIELDS SEARCHED</b>  Minimum documentation searched (classification system followed by classification symbols) IPC A61K + keywords: Parasit, Antiparasit, Benzimidazole, Thiabendazole, Albendazole, Cambendazole, Fenbendazole, Mebendazole, Oxfendazole, Oxibendazole, Parbendazole, Ciclobendazole, Flubendazole, Triclabendazole, Luxabendazole, Avermectin, Milbemycin, Abumectin, Ivermectin, Doramectin, Moxidectin Composit., Pharm., Dispers., Lipid, Protein, matrix, casein, gelatin  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) WPAT CASM					
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>					
<b>Category*</b>	<b>Citation of document, with indication, where appropriate, of the relevant passages</b>	<b>Relevant to Claim No.</b>			
X	WO 91/08669 (SMITHKLINE BEECHAM CORPORATION) 27 June 1991 (27.06.91)	1-6, 13-19			
X	WO 92/08454 (BEECHAM GROUP PLC) 22 May 1992 (22.05.92)	1-6, 13-19			
X	GB 2094625 (CIBA-GEIGY AG) 22 September 1982 (22.09.82)	1-6, 13-19			
X	AU, A, 17927/83 (CIBA-GEIGY AG) 16 February 1984 (16.02.84)	1-6, 13-19			
<div style="display: flex; justify-content: space-between;"> <div> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.         </div> <div> <input checked="" type="checkbox"/> See patent family annex.         </div> </div>					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;">           * Special categories of cited documents :            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" earlier document but published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 33%; vertical-align: top;">           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "&amp;" document member of the same patent family         </td> <td style="width: 33%;"></td> </tr> </table>			* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family				
Date of the actual completion of the international search 5 September 1994 (05.09.94)		Date of mailing of the international search report 13 Sept 1994 (13.09.94)			
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA  Facsimile No. 06 2853929		Authorized officer  J HANSON  Telephone No. (06) 2832262			

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
X	AU,A, 66259/81 (BAYER AG) 23 July 1981 (23.07.81)	1, 3-6, 13-19
X	AU,A, 10311/83 (CIBA-GEIGY AG) 21 July 1983 (21.07.83)	1-6, 13-19
X	AU,A, 69739/87 (CIBA-GEIGY AG) 10 September 1987 (10.09.87)	1-6, 13-19
X	EP,A1, 125004 (MERCK AND CO, INC) 14 November 1984 (14.11.84)	1-6, 13-19
X	US 4587247 (LINN et al) 6 May 1986 (06.05.86)	1-6, 13-19
X	EP,A1, 074758 (MERCK AND CO, INC) 23 March 1983 (23.03.83)	1-6, 13-19
X	EP,A2, 288205 (BEECHAM GROUP PLC) 26 October 1988 (26.10.88)	1-6, 13-19
X	EP,A1, 465121 (MERCK AND CO, INC) 8 January 1992 (08.01.92) See pages 5 and 6	1-6, 13-19
Y	US 4547491 (MERCK AND CO, INC) 15 October 1985 (15.10.85)	1-6, 13-19

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
WO	91/08669	AU	68715/91	EP	505389	JP	5504334
WO	92/08454	AU	88750/91	GB	9024926		
GB	2094625	AU	81611/82	DE	3260986	EP	60810
		US	4436737				
AU	17927/83	EP	101412	DE	3379497	GB	8320650
AU	66259/81	DE	3001519	EP	33825		
AU	10311/83	EP	84516	DE	3361358	GB	2113091
AU	69739/87	EP	237482	JP	62207279	US	4978677
EP	125004	AU	26602/84	DE	3462995	JP	59205321
US	4587247	AU	54004/86	DE	3673664	EP	193347
EP	74758	AU	87909/82	DE	3272017	JP	5016431
		US	4457920				
EP	288205	GB	8709327	JP	63277682		
EP	465121	AU	79392/91	JP	5306294	US	5288710
US	4547491	AU	45083/85	DE	3563850	JP	61036280
END OF ANNEX							